Efficacy and Safety of A Collagen Bupivacaine Implant in Patients After Gastrointestinal Surgery
A Phase II, Randomized, Single-dose, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Pharmacokinetic Profile of the CollaRx Bupivacaine Implant in Patients After Gastrointestinal Surgery
Sponsor: Innocoll
Terminated
Business decision
Other terminated trials from Innocoll
Other Pain, Postoperative trials with similar outcome
Listed as NCT00661466, this PHASE2 trial focuses on Pain, Postoperative and remains terminated or withdrawn. Sponsored by Innocoll, it has been updated 10 times since 2008, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Dec 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Dec 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
▶ Show 5 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Dec 2020 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Jul 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Innocoll
- Premier Research
For direct contact, visit the study record on ClinicalTrials.gov .